Cargando…

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy

BACKGROUND: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. In that study, mean body weight was decreased by 3.5 kg (4.3% of the baseline value) after ipraglifloz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagai, Yoshio, Fukuda, Hisashi, Kawanabe, Shin, Nakagawa, Tomoko, Ohta, Akio, Tanaka, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436566/ https://www.ncbi.nlm.nih.gov/pubmed/30937121 http://dx.doi.org/10.14740/jocmr3785

Ejemplares similares

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
por: Inoue, Hideka, et al.
Publicado: (2019)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
por: Choi, Min-Koo, et al.
Publicado: (2020)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
por: Nagashima, Shuichi, et al.
Publicado: (2020)

The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
por: Okura, Tsuyoshi, et al.
Publicado: (2022)

The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
por: Takeda, Akihiko, et al.
Publicado: (2017)

Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
por: Ishii, Satoshi, et al.
Publicado: (2019)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
por: Sargeant, Jack Alistair, et al.
Publicado: (2019)

Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study
por: Okada, Junichi, et al.
Publicado: (2020)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
por: Kashiwagi, Atsunori, et al.
Publicado: (2013)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
por: Saito, Masako, et al.
Publicado: (2020)

Case report of superior mesenteric artery syndrome that developed in a lean type 2 diabetes patient and was associated with rapid body weight loss after sodium–glucose cotransporter 2 inhibitor administration
por: Hirai, Taro, et al.
Publicado: (2020)

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
por: Post, Adrian, et al.
Publicado: (2020)

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
por: Matsuba, Ren, et al.
Publicado: (2018)

Are Fat Mass and Lean Mass Associated with Grip Strength in Adolescents?
por: Confortin, Susana Cararo, et al.
Publicado: (2022)

Impact of glycogen resynthesis on lean mass
por: Ormes, Jacob A, et al.
Publicado: (2014)

Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
por: Nagai, Yoshio, et al.
Publicado: (2021)

Influence of different sports on fat mass and lean mass in growing girls
por: Ubago-Guisado, Esther, et al.
Publicado: (2017)

Lean Mass in Childhood Obesity: A Key Determinant of Ventricular Mass?
por: Christopher, Adam B.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
por: Yasuda, Megumi, et al.
Publicado: (2019)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
por: Saito, Masako, et al.
Publicado: (2019)

Lean mass and peak bone mineral density
por: Nguyen, Huy G., et al.
Publicado: (2020)

Decreasing Lean Body Mass with Age: Challenges and Opportunities for Novel Therapies
por: Boutari, Chrysoula, et al.
Publicado: (2017)

Regulation of Lean Mass, Bone Mass, and Exercise Tolerance by the Central Melanocortin System
por: Braun, Theodore P., et al.
Publicado: (2012)

A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor
por: Fujita, Yukihiro, et al.
Publicado: (2020)

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
por: Min, Kyung-Wan, et al.
Publicado: (2017)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Iodide Binding in Sodium-Coupled Cotransporters
por: Vergara-Jaque, Ariela, et al.
Publicado: (2017)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Left ventricular mass correlates with lean body mass in patients with disease-associated wasting
por: Molfino, Alessio, et al.
Publicado: (2014)

Development of Novel Methods to Define Deficits in Appendicular Lean Mass Relative to Fat Mass
por: Weber, David, et al.
Publicado: (2016)

Associations of fat mass and muscle function but not lean mass with cognitive impairment: The Yishun Study
por: Tou, Nien Xiang, et al.
Publicado: (2021)

Predicted fat mass and lean mass in relation to all‐cause and cause‐specific mortality
por: Liu, Mengyi, et al.
Publicado: (2022)

Increasing lean muscle mass: nutritional and periodization strategies
por: Morton, James P
Publicado: (2015)

The McLean Hospital, Waverley, Mass., U.S.A.
Publicado: (1894)

Cannot write session to /tmp/vufind_sessions/sess_kokehabmp1uevo353tbhfm6gmf